Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992168 | 0.93 | — | — | |
| SCHEMBL4481772 | 0.90 | ALDH1A1 (0.33) | ALDH1A1TSHRCA2ABCB11CYP3A4 | |
| SCHEMBL8673647 | 0.83 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL31438278 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP3A4 | |
| SCHEMBL20425437 | 0.82 | MEN1 (0.50) | ALDH1A1TSHR | |
| SCHEMBL22609539 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP3A4 | |
| SCHEMBL11100889 | 0.82 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL7074845 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL31669602 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL26135931 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503980-A2 | SUBSTITUTED HYDROXYETHYLAMINES | Elan Pharmaceuticals, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| WO-2003072535-A2 | SUBSTITUTED HYDROXYETHYLAMINES | ELAN PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-10221255-B2 | Composition for the immediate stopping of a free-radical polymerization | BASF SE (DE) | 2019-03-05 | — | — | US | disclosed |
| US-20180171035-A1 | COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION | BASF SE (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3310819-A1 | COMPOSITION FOR IMMEDIATELY ENDING RADICAL POLYMERIZATION | BASF SE (DE) | 2018-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221255-B2 | Composition for the immediate stopping of a free-radical polymerization | FASTKD5, TYK2, FASTKD1 | ALDH1A1 1387/4885TSHR 4618/4885CA2 3416/4885 |
| US-20180171035-A1 | COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION | FASTKD5, TYK2, FASTKD1 | ALDH1A1 1387/4885TSHR 4618/4885CA2 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.